•  
  •  
 

Abstract

BACKGROUND: A proliferation-inducing ligand (APRIL) is a member of tumor necrosis factor family which plays an important role in B-cell development. It activates chronic lymphocytic leukemia (CLL) cells by reacting with its receptors, enhancing immune recognition, proliferation, and survival of the leukemia cells. OBJECTIVE: To assess the level of APRIL in newly diagnosed CLL patients in comparison with the control group and to correlate between the plasma APRIL level and hematological parameters and clinical Binet stages. PATIENTS AND METHODS: This case-control study was conducted on 40 adult newly diagnosed CLL patients with 40 healthy individuals served as controls.  Plasma APRIL levels were tested by ELISA. RESULTS: plasma APRIL level in CLL patients was significantly higher than those of healthy control group (P-value < 0.001). There were statistically insignificant correlations between APRIL level and hematological parameters. There was significant association between absence of splenomegaly and higher APRIL level (P=0.011), while no significant statistical differences were found with lymphadenopathyand hepatomegaly. There was no significant association between plasma APRIL level and Binet stages (P=0.180). CONCLUSION: There were insignificant correlations between APRIL level and hematological parameters and Binet stage. APRIL level was not found to be a useful marker to predict prognosis in patients with CLL.  

DOI

10.52573/ipmj.2021.174637

Download

Share

COinS